Litigation Details for OTSUKA PHARMACEUTICAL CO. LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

OTSUKA PHARMACEUTICAL CO. LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

Docket		Date Filed	2014-10-10
Court	District Court, D. New Jersey	Date Terminated	2016-08-09
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	Plaintiff	Referred To	Magistrate Judge Karen M. Will
Patents	7,053,092; 8,017,615; 8,580,796; 8,642,600; 8,642,760; 8,759,350
Link to Docket	External link to docket

Details for OTSUKA PHARMACEUTICAL CO. LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-10-10	1		of U.S. Patent No. 8,580,796 (“the ’796 patent”) and U.S. Patent No. 8,642,760 (“the ’760 patent”), arising… FOR PATENT INFRINGEMENT 11. The U.S. Patent and Trademark Office (“PTO”) issued the ’796 patent on November… of the ’796 patent is attached as Exhibit A. 12. Otsuka is the owner of the ’796 patent by virtue of…The ’796 patent expires on March 25, 2023 (including pediatric exclusivity). 14. The ’796 patent is directed… of the ’760 patent is attached as Exhibit B. 26. Otsuka is the owner of the ’760 patent by virtue of	External link to document
2015-04-16	105		product, U.S. Patent Nos. 5,006,528 (“the ’528 patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (…identifies the ’528 patent, the ’092 patent, the ’615 patent, the ’796 patent, the ’600 patent, the ’760 patent… (“the ’615 patent”), 8,580,796 (“the ’796 patent”), 8,642,600 (“the ’600 patent”), 8,642,760 (“…(“the ’760 patent”), and 8,759,350 (“the ’350 patent”). As the lengthy exclusivity period… for the original compound patent covering Abilify®, the ’528 patent, comes to close on April 20	External link to document